iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/19252775/
Clinical predictors of early second event in patients with clinically isolated syndrome - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;256(7):1061-6.
doi: 10.1007/s00415-009-5063-0. Epub 2009 Mar 1.

Clinical predictors of early second event in patients with clinically isolated syndrome

Ellen M Mowry  1 , Mila Pesic, Barbara Grimes, Serina R Deen, Peter Bacchetti, Emmanuelle Waubant
Affiliations

Clinical predictors of early second event in patients with clinically isolated syndrome

Ellen M Mowry et al. J Neurol. 2009 Jul.

Abstract

This study aimed to determine the predictors of increased risk of a second demyelinating event within the first year of an initial demyelinating event (IDE) suggestive of early multiple sclerosis (MS). Patients with MS or clinically isolated syndrome (CIS) seen at the UCSF MS Center within one year of the IDE were studied. Univariate and multivariate Cox models were used to analyze predictors of having a second event within 1 year of the IDE. Of 330 patients with MS/CIS, 111 had a second event within 1 year. Non-white race/ethnicity (HR = 2.39, 95% CI [1.58, 3.60], p < 0.0001) and younger age (HR for each 10-year decrease in age = 1.51, 95% CI [1.28, 1.80], p < 0.0001) were strongly associated with an increased risk of having a second event within one year of onset. Having a lower number of functional systems affected by the IDE was also associated with an increased risk of early second event (HR for every one less FS involved = 1.31, 95% CI [1.06, 1.61], p = 0.011). These results were similar after adjusting for treatment of the IDE with steroids and disease-modifying therapy. Non-white race/ethnicity, younger age, and a lower number of FS affected by the IDE are associated with a substantially increased hazard ratio for a second demyelinating event within 1 year. Since early relapse is predictive of worse long-term outcome, identifying and treating such patients after the IDE may be of benefit to them.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Relapse-free survival curves by age (a), race (b), and number of functional systems (c)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/ana.20703', 'is_inner': False, 'url': 'https://doi.org/10.1002/ana.20703'}, {'type': 'PubMed', 'value': '16283615', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16283615/'}]}
    2. Polman CH, Reingold SG, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann Neurol 58:840–846 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/archneur.63.4.614', 'is_inner': False, 'url': 'https://doi.org/10.1001/archneur.63.4.614'}, {'type': 'PubMed', 'value': '16606781', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16606781/'}]}
    2. Frohman E, Havrdova E, Lublin F et al (2006) Most patients with multiple sclerosis or clinically isolated demyelinating syndrome should be treated at time of diagnosis. Arch Neurol 63:614–619 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1468-1331.2007.01810.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1468-1331.2007.01810.x'}, {'type': 'PubMed', 'value': '17662009', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17662009/'}]}
    2. Ramsaransing GSM, DeKeyser J (2007) Predictive value of clinical characteristics for “benign” multiple sclerosis. Eur J Neurol 14:885–889 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1212/01.wnl.0000187122.71735.1f', 'is_inner': False, 'url': 'https://doi.org/10.1212/01.wnl.0000187122.71735.1f'}, {'type': 'PubMed', 'value': '16344520', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16344520/'}]}
    2. Held U, Heigenhauser L, Shang C et al (2005) Predictors of relapse rate in MS clinical trials. Neurology 65:1769–1773 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00415-008-0743-8', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00415-008-0743-8'}, {'type': 'PubMed', 'value': '18204919', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/18204919/'}]}
    2. Hirst C, Ingram G, Pearson O et al (2008) Contribution of relapses to disability in multiple sclerosis. J Neurology 255:280–287 - PubMed

Publication types

MeSH terms